A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) With or Without Durvalumab in Combination With Chemotherapy in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma
Phase of Trial: Phase I/II
Latest Information Update: 20 Jan 2019
At a glance
- Drugs Durvalumab (Primary) ; Oleclumab (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Oxaliplatin; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors MedImmune
- 26 Dec 2018 New source identified and integrated (European Clinical Trials Database record: EudraCT2018-001028-21).
- 18 Dec 2018 Planned End Date changed from 25 May 2021 to 10 May 2021.
- 18 Dec 2018 Planned primary completion date changed from 25 May 2021 to 10 May 2021.